Ionis Pharmaceuticals (NASDAQ:IONS) EVP Brian Birchler Sells 8,000 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Brian Birchler sold 8,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $76.17, for a total value of $609,360.00. Following the sale, the executive vice president directly owned 48,826 shares of the company’s stock, valued at $3,719,076.42. The trade was a 14.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Brian Birchler also recently made the following trade(s):

• On Wednesday, October 15th, Brian Birchler sold 12,425 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $72.23, for a total value of $897,457.75.
• On Tuesday, October 14th, Brian Birchler sold 11,475 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $72.03, for a total value of $826,544.25.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $73.55 on Friday. The firm has a market cap of $11.91 billion, a price-to-earnings ratio of -43.52 and a beta of 0.33. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $76.78. The firm’s fifty day moving average price is $67.11 and its 200 day moving average price is $48.10.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 45.29%. The business had revenue of $157.00 million for the quarter, compared to analyst estimates of $131.75 million. During the same period in the previous year, the business posted ($0.95) earnings per share. The business’s revenue was up 17.2% compared to the same quarter last year. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Ionis Pharmaceuticals in the third quarter worth approximately $25,000. Golden State Wealth Management LLC boosted its holdings in shares of Ionis Pharmaceuticals by 198.4% during the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after buying an additional 250 shares during the period. Mather Group LLC. acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth about $27,000. Allworth Financial LP grew its stake in shares of Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock worth $29,000 after acquiring an additional 517 shares during the last quarter. Finally, Signaturefd LLC increased its stake in Ionis Pharmaceuticals by 45.6% during the first quarter. Signaturefd LLC now owns 1,382 shares of the company’s stock valued at $42,000 after acquiring an additional 433 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IONS shares. Citigroup lifted their price target on Ionis Pharmaceuticals from $69.00 to $84.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. TD Cowen boosted their price objective on shares of Ionis Pharmaceuticals from $59.00 to $99.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Oppenheimer raised their price target on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. Jefferies Financial Group increased their target price on Ionis Pharmaceuticals from $83.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $89.00 price target (up from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $83.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.